Search

Roche Holding AG

Fermé

SecteurSoins de santé

293.8 -2.59

Résumé

Variation du prix de l'action

24h

Actuel

Min

291

Max

301.6

Chiffres clés

By Trading Economics

Revenu

6.3B

Ventes

31B

P/E

Moyenne du Secteur

29.748

63.778

Rendement du dividende

3.1

Marge bénéficiaire

20.347

Employés

103,249

EBITDA

11B

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

3.10%

2.39%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

233B

Ouverture précédente

296.39

Clôture précédente

293.8

Sentiment de l'Actualité

By Acuity

48%

52%

176 / 386 Classement par Healthcare

Roche Holding AG Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

12 mars 2025, 09:23 UTC

Principaux Mouvements du Marché

Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche

30 janv. 2025, 09:36 UTC

Résultats

Roche Expects Growth to Continue This Year After Sales, Earnings Beat Forecasts -- Update

30 janv. 2025, 06:32 UTC

Résultats

Roche Expects Sales, Earnings Growth After Better-Than-Expected Results

26 nov. 2024, 15:27 UTC

Acquisitions, Fusions, Rachats

Trending: Roche to Buy Poseida Therapeutics for Up to $1.5 Billion

31 mars 2025, 09:31 UTC

Actions en Tendance

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

13 mars 2025, 07:46 UTC

Market Talk

Roche's Zealand Pharma Deal Signals Commitment to Obesity Drug Market -- Market Talk

12 mars 2025, 16:34 UTC

Actualités

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal -- Update

12 mars 2025, 08:51 UTC

Market Talk

Roche's Multiple-Sclerosis Drug Sales Potential Fuels Rating Upgrade -- Market Talk

12 mars 2025, 08:18 UTC

Market Talk

Roche's Obesity Deal With Zealand Pharma Makes Sense, Vontobel Says -- Market Talk

13 févr. 2025, 11:43 UTC

Market Talk

Roche's Growth Fueled by Key Drugs, Promising Pipeline -- Market Talk

30 janv. 2025, 07:56 UTC

Market Talk
Résultats

Roche Delivered Solid Results But Diagnostics' Profitability Disappoints -- Market Talk

30 janv. 2025, 06:04 UTC

Résultats

Roche Expects 2025 EPS Growth in High Single Digit Range at Constant Currency

30 janv. 2025, 06:04 UTC

Résultats

Roche Expects 2025 Sales Increase in Mid Single Digit Range at Constant Currency

30 janv. 2025, 06:04 UTC

Résultats

Roche Issues 2025 View

30 janv. 2025, 06:03 UTC

Résultats

Roche Raises Dividend to CHF9.70 Vs CHF9.60

30 janv. 2025, 06:03 UTC

Résultats

Roche 2024 Core Operating Profit CHF20.82B

30 janv. 2025, 06:03 UTC

Résultats

Roche 2024 Net Pft CHF9.19B

30 janv. 2025, 06:02 UTC

Résultats

Analysts Saw 2024 Core EPS at CHF18.59

30 janv. 2025, 06:02 UTC

Résultats

Roche 2024 Core EPS CHF18.80

30 janv. 2025, 06:02 UTC

Résultats

Roche 2024 Sales EUR60.50B

30 janv. 2025, 06:02 UTC

Résultats

Analysts Saw Roche 2024 Revenue at CHF60.41B

30 janv. 2025, 06:01 UTC

Résultats

Roche 2024 Sales CHFB

28 janv. 2025, 10:30 UTC

Actualités

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

28 janv. 2025, 07:24 UTC

Market Talk

Roche's Breast Cancer Drug Extends Life of Patients -- Market Talk

15 janv. 2025, 10:22 UTC

Market Talk

Swiss Companies Pay Record Level of Dividends as Buybacks Fall -- Market Talk

8 janv. 2025, 06:15 UTC

Acquisitions, Fusions, Rachats

Roche: 66.11% of Poseida's Shares Were Validly Tendered in Offer

8 janv. 2025, 06:12 UTC

Acquisitions, Fusions, Rachats

Roche Intends to Complete Acquisition of Poseida Therapeutics Later Wednesday

16 déc. 2024, 22:03 UTC

Actualités

Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com

13 déc. 2024, 16:36 UTC

Market Talk

Swiss Equities an Overweight Pick Next Year -- Market Talk

26 nov. 2024, 16:10 UTC

Acquisitions, Fusions, Rachats

Why This Gene-Therapy Company's Stock Is Rising 228% -- Barrons.com

Roche Holding AG prévision

Sentiment

By Acuity

176 / 386Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.